Showing results (201-210 of 209) with videos related to
Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 209 results.
The Journal of Clinical Endocrinology and Metabolism|October 8, 2019
Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes StudyBénédicte Gaborit, Jean-Baptiste Julla, Samaher Besbes, et al.Iscience|September 21, 2021
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cellsXiaodong Zhuang, Senko Tsukuda, Florian Wrensch, et al.The Journal of Clinical Investigation|September 11, 2025
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease modelsEmilie Crouchet, Eugénie Schaeffer, Marine A Oudot, et al.Egastroenterology|March 24, 2025
Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver diseaseArmando Andres Roca Suarez, Frank Jühling, Julien Moehlin, et al.Journal of Hepatology|August 22, 2025
Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitisFabio Del Zompo, Emilie Crouchet, Tessa Ostyn, et al.Nature Biotechnology|March 24, 2015
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibodyLaurent Mailly, Fei Xiao, Joachim Lupberger, et al.Science Translational Medicine|June 3, 2026
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma modelsZeina Nehme, Marion Muller, Jade Brochon, et al.Journal of Hepatology|October 29, 2022
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironmentNatascha Roehlen, Marion Muller, Zeina Nehme, et al.Science Translational Medicine|December 21, 2022
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticityNatascha Roehlen, Antonio Saviano, Houssein El Saghire, et al.Pageof 21